Substantially more upside than downside at the current price.
It's only a matter of time before it spikes higher and trends up.
It's unfortunate that his Yahoo screen name is "SellPVCT". Poor planning by the company.
Better opportunity at a dime than ARNA at $7.30.
Read the recent Yahoo news.
Zacks' analyst Jason Napadano says it's worth twice the current price and has a buy rating on $AMBS.
The holders of the warrants will try to keep the share price above .10 for the twenty sessions to get the shares at .03 and the shorts will try to stop this from happening to insure massive dilution.
Interesting weeks ahead.
This could be a major problem for Amarantus. The warrants convert to about 172,500,000 shares for about $5,000,000 or about .03/share.
If the warrants fail to convert then the company will have to do another secondary offering which would be below .03/share since the 172,500,000 shares currently in play would still be there.
It's likely that the company would then have a billion shares outstanding.
The Dreamboat has been touted as a more efficient delivery system than the Medtone. Therefore it is reasonable to assume that the concentraion of Afrezza is greater when using the Dreamboat. Therefore it's likely to assume that if the Afrezza is an irritant it would be more noticeable in the Dreamboat which it was.